Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03694925 · ClinicalTrials.gov registry record
Diagnostic Utility of a Novel Point-of-Care Test of Calprotectin for Revision Total Knee Arthroplasty
A clinical trial, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- 156
- Enrollment target
NCT03694925: Completed study, sponsored by The Cleveland Clinic.
NCT03694925 is a clinical trial that has completed, run by The Cleveland Clinic. The registered enrollment target is 156 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03694925 has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- 156 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether there are quantifiable differences in the level of calprotectin in the synovial fluid that allow separation of different modes of joint implant failure (e.g. infected, aseptic loosening). A subset of primary TKA patients (with history of OA) will be included as a baseline.
Primary Outcome
lateral flow point of care test
Interventions
- DIAGNOSTIC_TEST Calprotectin test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2018-10-29 |
| Est. Completion | 2020-03-04 |
What the finished NCT03694925 record still lists
NCT03694925 is an observational study that tracks outcomes without assigning an intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Calprotectin test is the first listed.
NCT03694925 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03694925 about?
NCT03694925 is a clinical study titled "Diagnostic Utility of a Novel Point-of-Care Test of Calprotectin for Revision Total Knee Arthroplasty". The purpose of this study is to investigate whether there are quantifiable differences in the level of calprotectin in the synovial fluid that allow separation of different modes of joint implant failure (e.g. infected, aseptic loosening). A subset of primary TKA patients (with history of OA) will b...
What is the current status of trial NCT03694925?
This trial is currently completed. The enrollment target is 156 participants. The study started on 2018-10-29. Estimated completion is 2020-03-04.
What interventions are being tested in trial NCT03694925?
The interventions under investigation include: Calprotectin test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03694925?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI